Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID

Author(s):  Riepl Mike, Kaiser Joe

Issue:  Jul/Aug 2023 - Volume 27, Number 4
View All Articles in Issue

Page(s):  284-293

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 1
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 2
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 3
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 4
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 5
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 6
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 7
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 8
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 9
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 10

Download in electronic PDF format for $75

Abstract:  People infected by severe acute respiratory coronavirus 2 (SARS-CoV-2) risk the development of not only acute coronavirus- disease–2019 (COVID-19) — the signs and symptoms of which range from none to severe illness that requires intensive treatment — but also long COVID (i.e., chronic COVID), a cyclical, progressive, multiphasic illness characterized by myriad debilitating conditions that persist long term. In some patients, those sequelae result in psychiatric disorders that can lead to suicide or other forms of self-harm, incidences of which have increased exponentially since before the COVID pandemic. It has been suggested that long COVID develops in an estimated 10% to 35% of people diagnosed as having COVID-19. Because the success of therapy for either form of COVID can be complicated by each patient’s pharmacogenomic profile, personal treatment preferences, medical needs, and/or dosing requirements, we have found that in some people so afflicted, manufactured medications are ineffective or intolerable, and that for those individuals, a customized compound often provides relief and promotes recovery. The primary focus of this article is long COVID. The pathogenesis of that disease is reviewed, therapies for the signs and symptoms it engenders are examined, and 2 compounded formulations effective in treating both acute and chronic COVID-19 are presented.

Related Keywords: Mike Riepl, RPh, Joe Kaiser, PharmD, RPh, severe acute respiratory coronavirus 2, SARS-CoV-2, acute coronavirus disease 2019, COVID-19, long COVID, chronic COVID, suicidal thinking, self harm, suffering, burden of disease, quality of life, inflammation, cytokine release syndrome, cytokine storm, immune system dysregulation, microclot formation, tissue perfusion, ischemia, fatigue, dyspnea, post exertional malaise, brain fog, arthralgias, paresthesias, dysautonomia, Toll-like receptor 4, TLR4 antagonists, statins, low-dose naltrexone, formulations, theophylline nasal spray, opioid receptor blockade, naltrexone hydrochloride troche

Related Categories: FORMULATIONS, MENTAL HEALTH, ALLERGY/IMMUNOLOGY/INFLAMMATION, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike
, Kaiser Joe
Jul/Aug 2023
Pg. 284-293

Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Riepl Mike
Jan/Feb 2023
Pg. 12-21

Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Riepl Mike
, Kaiser Joe
May/Jun 2023
Pg. 192-200

Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Riepl Mike
, Kaiser Joe
Sep/Oct 2023
Pg. 368-380

Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment
Riepl Mike
Mar/Apr 2023
Pg. 98-107

Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
Jul/Aug 2020
Pg. 287-295

PreScription: COVID-19 and Compounding Pharmacists
Allen Loyd V Jr
Jul/Aug 2020
Pg. 268

Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Nogales Luis Marcos
, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Sep/Oct 2020
Pg. 358-364

Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Roberts Patricia A
, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
Mar/Apr 2021
Pg. 109-113

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF
Allen Loyd V Jr
Jul/Aug 2020
Pg. 316

Calculations
Stockton Shelly J
Jul/Aug 2020
Pg. 310

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

PreScription: Endemics, Epidemics, and Pandemics
Allen Loyd V Jr
Jul/Aug 2021
Pg. 268

A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Brunner Scott
Jul/Aug 2021
Pg. 296-297

Calculations
Stockton Shelly J
May/Jun 2021
Pg. 230-231

It's Time for a New Philosophy
Brunner Scott
Sep/Oct 2021
Pg. 386-387

Return to Top